 BRYAN, Texas, Dec. 01, 2020 GLOBE NEWSWIRE -- iBio, Inc. NYSEA:IBIO iBio or the Company, a biotech innovator and biologics contract development and manufacturing organization CDMO, today announced that it has entered into its first Statement of Work SoW under a Master Services Agreement with Belgium-based ATB Therapeutics atbtherapeutics to produce its bioengineered antibody-toxin fusion proteins using iBios FastPharming System. 